ANIP — ANI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $1.67bn
- $1.90bn
- $883.37m
ANI Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: ANI Pharmaceuticals Q2 Adjusted EPS USD 1.02 Vs. IBES Estimate USD 0.95
ANI Pharmaceuticals Inc expected to post earnings of 95 cents a share - Earnings Preview
Brief: ANI Pharmaceuticals Announces FDA Approval And Launch Of Naproxen Delayed-Release Tablets, USP
Brief: ANI Pharmaceuticals Announces The FDA Approval And Launch Of Naproxen Delayed-Release Tablets, USP
Alimera Sciences soars nearly 80% on ANI Pharma buyout
Brief: Ani Pharmaceuticals Expands Rare Disease Business Through Acquisition Of Alimera Sciences
Brief: Ani Pharmaceuticals Announces The Launch Of Kionex® Suspension
ANI Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 1.21 Vs. IBES Estimate USD 1
ANI Pharmaceuticals Inc expected to post earnings of $1.00 a share - Earnings Preview
ANI Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: ANI Pharmaceuticals Q4 Adjusted EPS USD 1 Vs. IBES Estimate USD 0.85
ANI Pharmaceuticals Inc expected to post earnings of 86 cents a share - Earnings Preview
Brief: ANI Pharmaceuticals-Unit Got Into Deal With 1540700 Ontario Limited For Purchase and Sale Of Co's Oakville, Ontario Former Manufacturing Facility
Brief: ANI Pharmaceuticals Announces Launch Of Pentoxifylline Extended-Release Tablets, USP
Brief: ANI Pharmaceuticals Announces FDA Approval And Launch Of Indomethacin Oral Suspension, USP
Brief: ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results And Raises 2023 Guidance
Brief: ANI Pharmaceuticals Q3 Adjusted EPS USD 1.27